Literature DB >> 22795095

An overview of a 30-year experience with amniocentesis in a single tertiary medical center in Taiwan.

Yi-Wen Chang1, Chia-Ming Chang, Pi-Lin Sung, Ming-Jie Yang, Wai Hou Li, Hsin-Yang Li, Ling-Chao Chen, Ling-Yi Cheng, Yu-Ling Lai, Yung-Yung Cheng, Wen-Hsun Chang, Kuan-Chong Chao, Peng-Hui Wang.   

Abstract

OBJECTIVE: Amniocentesis is a popular and effective prenatal diagnostic tool for chromosomal disorders. It is well-established that the risk of chromosomal abnormalities increases with maternal age; however, other related indications are seldom reported. Herein, we report our 30-year experience with amniocentesis from a single medical center, focusing on the indications and rates of abnormality.
MATERIAL AND METHODS: A retrospective review of 16,749 pregnant women in the mid-trimester between January 1981 and December 2010 was conducted. The medical records were analyzed.
RESULTS: The indications for amniocentesis were advanced maternal age (≥ 34 years old) (n=10,970, 65.5%), increasing-risk maternal triple-marker Down's screening test (≥ 1/270) (n=2090, 12.5%), history of abnormal offspring birth (n=792, 4.7%), abnormal ultrasound findings (n=484, 2.9%), parent with abnormal karyotype (n=252, 1.5%), family history of chromosomal abnormality (n=183, 1.1%), drug and radiation exposure (n=165), abnormal chorionic villus sampling (CVS) results (n=25), intrauterine fetal death (n=50), and other non-specific causes (n=1662, 9.9%). The rate of abnormality for each indication was 16% in the abnormal CVS group, 12% in the intrauterine fetal death group, 11.5% for parental chromosomal abnormality, 8.7% in the abnormal ultrasound finding group, 3.0% in the increasing-risk maternal triple-marker Down's screening test group, 2.5% in the advanced maternal age group, 1.5% for other non-specific causes, 1.4% for history of abnormal offspring birth, and 1.1% for family history of chromosomal abnormality.
CONCLUSIONS: Both parents with abnormal karyotype and abnormal ultrasound findings are indications for which consideration of further amniocentesis is highly recommended.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2012        PMID: 22795095     DOI: 10.1016/j.tjog.2012.04.007

Source DB:  PubMed          Journal:  Taiwan J Obstet Gynecol        ISSN: 1028-4559            Impact factor:   1.705


  6 in total

1.  Chromosome abnormalities diagnosed in utero: a Japanese study of 28 983 amniotic fluid specimens collected before 22 weeks gestations.

Authors:  Miyuki Nishiyama; Jim Yan; Junko Yotsumoto; Hideaki Sawai; Akihiko Sekizawa; Yoshimasa Kamei; Haruhiko Sago
Journal:  J Hum Genet       Date:  2015-01-08       Impact factor: 3.172

Review 2.  Prenatal diagnosis by chromosomal microarray analysis.

Authors:  Brynn Levy; Ronald Wapner
Journal:  Fertil Steril       Date:  2018-02       Impact factor: 7.329

3.  Changes in and Efficacies of Indications for Invasive Prenatal Diagnosis of Cytogenomic Abnormalities: 13 Years of Experience in a Single Center.

Authors:  Jinlai Meng; Chelsea Matarese; Julianna Crivello; Katherine Wilcox; Dongmei Wang; Autumn DiAdamo; Fang Xu; Peining Li
Journal:  Med Sci Monit       Date:  2015-07-05

4.  Analysis of chromosome 22q11 copy number variations by multiplex ligation-dependent probe amplification for prenatal diagnosis of congenital heart defect.

Authors:  Jingjing Zhang; Dingyuan Ma; Yan Wang; Li Cao; Yun Wu; Fengchang Qiao; An Liu; Li Li; Ying Lin; Gang Liu; Cuiyun Liu; Ping Hu; Zhengfeng Xu
Journal:  Mol Cytogenet       Date:  2015-12-29       Impact factor: 2.009

5.  Frequency and clinical significance of chromosomal inversions prenatally diagnosed by second trimester amniocentesis.

Authors:  Chih-Wei Chien; An-Shine Chao; Yao-Lung Chang; Kuan-Ju Chen; Hsiu-Huei Peng; Yu-Ting Lin; Angel Chao; Shuenn-Dyh Chang
Journal:  Sci Rep       Date:  2022-02-09       Impact factor: 4.379

6.  20-year experience on prenatal diagnosis in a reference university medical genetics center in Turkey

Authors:  Burak Durmaz; Hilmi Bolat; Zehra Cengisiz; Fuat Akercan; Tuba Sözen Türk; Erhan Parıltay; Aslı Ece Solmaz; Mert Kazandı; Emin Karaca; Asude Durmaz; Ayça Aykut; Sermet Sağol; Haluk Akın; Ferda Özkınay; ÖzgÜr Çoğulu
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.